ReviewFuture medicinal chemistry2012
Opioid glycopeptide analgesics derived from endogenous enkephalins and endorphins.
Review in Future medicinal chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 47 citations in OpenAlex.
- The role of time interval elimination on pain control of preterm infants by sucrose administration.European journal of clinical pharmacology · 2023Trial
- Cyclic Glycopeptide Analogs of Endomorphin-1 Provide Highly Effective Antinociception in Male and Female Mice.ACS medicinal chemistry letters · 2024Article
- Structure-Based Design of Glycosylated Oxytocin Analogues with Improved Selectivity and Antinociceptive Activity.ACS medicinal chemistry letters · 2023Article
- Peptidomimetics and Their Applications for Opioid Peptide Drug Discovery.Biomolecules · 2022Review
- Potential Role of Yoga Intervention in the Management of Chronic Non-malignant Pain.Evidence-based complementary and alternative medicine : eCAM · 2022Review
- Design and Synthesis of Brain Penetrant Glycopeptide Analogues of PACAP With Neuroprotective Potential for Traumatic Brain Injury and Parkinsonism.Frontiers in drug discovery · 2022Article
- Synthesis and In Vitro Characterization of Glycopeptide Drug Candidates Related to PACAPMolecules (Basel, Switzerland) · 2021Article
- Nanotherapeutics in Neuropathologies: Obstacles, Challenges and Recent Advancements in CNS Targeted Drug Delivery Systems.Current neuropharmacology · 2021Article
- Behavioral pharmacology of the mixed-action delta-selective opioid receptor agonist BBI-11008: studies on acute, inflammatory and neuropathic pain, respiration, and drug self-administration.Psychopharmacology · 2020Article
- A tetrapeptide class of biased analgesics from an Australian fungus targets the µ-opioid receptor.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia.Neuropharmacology · 2018Article
- Comparing naturally occurring glycosylated forms of proline rich antibacterial peptide, Drosocin.Glycoconjugate journal · 2017Article
- CNS active O-linked glycopeptides.Frontiers in chemistry · 2015Review
- In Vitro Membrane Permeation Studies and in Vivo Antinociception of Glycosylated DmtACS medicinal chemistry letters · 2014Article
- Development of a bioavailable μ opioid receptor (MOPr) agonist, δ opioid receptor (DOPr) antagonist peptide that evokes antinociception without development of acute tolerance.Journal of medicinal chemistry · 2014Article
- Can amphipathic helices influence the CNS antinociceptive activity of glycopeptides related to β-endorphin?Journal of medicinal chemistry · 2014Article
- Translation of structure-activity relationships from cyclic mixed efficacy opioid peptides to linear analogues.Biopolymers · 2014Article
- Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.Journal of medicinal chemistry · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Over the past two decades, potent and selective analgesics have been developed from endogenous opioid peptides. Glycosylation provides an important means of modulating interaction with biological membranes, which greatly affects the pharmacodynamics and pharmacokinetics of the resulting glycopeptide analogues. Furthermore, manipulation of the membrane affinity allows penetration of cellular barriers that block efficient drug distribution, including the blood-brain barrier. Extremely potent and selective opiate agonists have been developed from endogenous peptides, some of which show great promise as drug candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.